This company seems to have been delisted
Reason: Acquired by Kyowa Kirin
Last recorded trade on: March 20, 2024
Source: https://www.ns-healthcare.com/news/kyowa-kirin-wraps-up-acquisition-of-orchard-therapeutics/
Reason: Acquired by Kyowa Kirin
Last recorded trade on: March 20, 2024
Source: https://www.ns-healthcare.com/news/kyowa-kirin-wraps-up-acquisition-of-orchard-therapeutics/
Orchard Therapeutics
ORTX
14,40 €
Share price
0.00%
Change (1 day)
223.57%
Change (1 year)
Orchard Therapeutics (ORTX) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : €0.10 Billion
According to Orchard Therapeutics 's latest financial reports the company's total liabilities are €0.10 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Orchard Therapeutics - Total liabilities on balance sheet (from 2017 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | €0.11 B | 13.26% |
| 2021-12-31 | €99.3 M | 19.16% |
| 2020-12-31 | €83.33 M | -6.73% |
| 2019-12-31 | €89.34 M | 86.84% |
| 2018-12-31 | €47.81 M | 426.91% |
| 2017-12-31 | €9.07 M | -54.12% |
| 2016-12-31 | €19.78 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novocure
NVCR | €0.76 B | 626.88% | Jersey |
 Novavax NVAX | €1.17 B | 1,021.76% | 🇺🇸 USA |
 Organovo ONVO | €3.58 M | -96.59% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | €0.10 B | 0.00% | 🇬🇧 UK |